Keywords: GlaxoSmithKline, ChemoCentryx, Traficet-EN, Inflammatory bowel syndrome, Crohn's disease

GlaxoSmithKline exercises option for ChemoCentryx’ Traficet-EN for IBD

Article | 12 January 2010

Print This

As part of a deal signed in 2006, UK drug giant GlaxoSmithKline has exercised its option to obtain an exclusive license ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in